As reported by Pillozzi and colleagues, low CD163+ levels are associated with favorable survival in synovial sarcoma, while high levels of CD163+ are associated with enhanced survival in embryonic rhabdomyosarcoma [17]. The gene discussed is CD163; the disease is synovial sarcoma.